10-K: CV Sciences Acquires Cultured Foods, Reports Mixed Financial Results in 10-K Filing

CV Sciences acquired Cultured Foods, a European plant-based food manufacturer, while reporting a slight decrease in net product sales but improved gross profit in its annual 10-K filing.

Summary

• CV Sciences acquired Cultured Foods, a European plant-based food manufacturer, on December 7, 2023.
• The company's net product sales decreased slightly by 1.2% to $16.0 million in 2023 compared to $16.2 million in 2022.
• Gross profit increased by 27.7% to $7.1 million in 2023, with gross margins improving from 34.2% to 44.3%.
• The company experienced a reduction in cost of goods sold by 16.3% due to lower shipping and production costs.
• Selling, general, and administrative expenses decreased by 19.4% to $9.7 million in 2023.
• Research and development expenses decreased by 50.8% to $0.2 million in 2023.
• The company reported a net income of $3.1 million in 2023, a significant improvement from a net loss of $8.2 million in 2022, primarily due to a $6.2 million benefit from the reversal of accrued payroll taxes.
• Adjusted EBITDA was a loss of $2.3 million in 2023, compared to a loss of $6.1 million in 2022.
• The company generated positive cash flow from operations of $2.3 million in 2023, which included $2.7 million in government receipts.
• As of December 31, 2023, the company had $1.3 million in cash and $1.8 million in working capital.
• The company is dependent on additional investment capital to fund operations and growth initiatives.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive signs such as improved profitability and cash flow, the company's dependence on external funding and the competitive landscape temper the overall sentiment. The acquisition of Cultured Foods is a positive strategic move, but its impact on the company's financials is yet to be fully realized.

Positives

• The acquisition of Cultured Foods expands the company's presence into the European plant-based food market.
• The company achieved a significant improvement in gross profit and gross margins.
• The company's net income improved significantly from a loss to a profit.
• The company generated positive cash flow from operations.
• The company reduced operating expenses, including selling, general, and administrative expenses and research and development expenses.

Negatives

• Net product sales decreased slightly by 1.2% compared to the previous year.
• The company is dependent on additional investment capital to fund operations and growth initiatives.
• The company has an accumulated deficit of $84.6 million.

Risks

• The company faces intense competition in the CBD-based consumer product industry.
• The company operates in a rapidly evolving market with a lack of a clear regulatory framework.
• The company is dependent on additional investment capital to fund operations and growth initiatives.
• The company's financial operating results and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
• Global economic conditions and rising inflation may adversely impact the company's business and financial position.

Future Outlook

Management anticipates that the company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives, and will continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities. The company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit.

Management Comments

• Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations and growth initiatives.
• Management implemented, and continues to make and implement, strategic cost reductions, including reductions in employee headcount, vendor spending, and the delaying of certain expenses related to our drug development activities.

Industry Context

The CBD-based consumer product industry is highly competitive and fragmented, with numerous companies vying for market share. The plant-based food market in Europe is also competitive and fragmented. The company is also developing cannabinoid therapeutics for a range of medical indications, which is a growing area of interest.

Comparison to Industry Standards

• The document mentions competitors such as Charlotte's Web Holdings Inc., cbdMD, Inc., and Medterra CBD, Inc. in the CBD market, indicating a competitive landscape.
• The company's gross margin of 44.3% is a positive sign, but it is important to compare this to industry averages to assess its competitiveness.
• The company's reliance on external funding is a common challenge for smaller companies in the CBD and plant-based food industries, but it is important to compare the company's cash position and burn rate to its peers.
• The company's drug development program is a unique aspect that could provide a competitive advantage if successful, but it also carries significant risk and requires substantial investment.

Legal Proceedings

• The company is involved in a shareholder derivative suit, a putative class action complaint, and a complaint filed by a former executive, all of which are ongoing.
• The company has agreed to a settlement in principle in the shareholder derivative suit, which is pending final court approval.

Related Party Transactions

• The company has a settlement agreement with its former CEO, Michael Mona Jr., which includes ongoing obligations and potential liabilities.

Stakeholder Impact

• Shareholders may be impacted by the company's dependence on external funding and the competitive landscape.
• Employees may be impacted by ongoing cost reductions, including potential reductions in headcount.
• Customers may benefit from the company's new product development and expansion into new markets.
• Suppliers may be impacted by the company's efforts to optimize its supply chain.

Next Steps

• The company will continue to make and implement strategic cost reductions.
• The company will seek additional investment capital to fund operations and growth initiatives.
• The company will continue to develop and launch new product lines and brands.
• The company will continue its development efforts for its drug candidate CVSI-007.

Key Dates

Keywords

CBD, hemp, plant-based food, acquisition, financial results, Cultured Foods, net sales, gross profit, operating expenses, net income, EBITDA, working capital, investment capital